{"url_path":"/sec/txg/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","accession_number":"0001628280-26-032388","cik":"0001770787","ticker":"TXG","issuer_name":"10x Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","primary_entity_key":"0001770787","primary_entity_name":"10x Genomics, Inc."},"word_count":154,"has_tables":true,"body_markdown":"Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.\n\nFollowing our acquisition of Scale Biosciences, Inc. in 2025, we made a milestone payment in the first quarter of 2026 in which a portion of the consideration consisted of the unregistered issuance of 396,584 shares of our Class A common stock, valued at $8.7 million. The sales of these securities were deemed to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon Section 4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder) as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions."}